Oramed Pharmaceuticals (XTAE:ORMP) Additional Paid-In Capital : ₪1,178.69 Mil(As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals Additional Paid-In Capital?

Oramed Pharmaceuticals's quarterly additional paid-in capital increased from Sep. 2023 (₪1,169.06 Mil) to Dec. 2023 (₪1,174.01 Mil) and increased from Dec. 2023 (₪1,174.01 Mil) to Mar. 2024 (₪1,178.69 Mil).

Oramed Pharmaceuticals's annual additional paid-in capital increased from Aug. 2021 (₪842.21 Mil) to Dec. 2022 (₪1,150.32 Mil) and increased from Dec. 2022 (₪1,150.32 Mil) to Dec. 2023 (₪1,174.01 Mil).

Oramed Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Oramed Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Additional Paid-In Capital Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

366.91

458.09

842.21

1,150.32

1,174.01

Oramed Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															1,159.64	1,166.11	1,169.06	1,174.01	1,178.69

Oramed Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Oramed Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (XTAE:ORMP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ORMP:USA OJU1:Germany

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.